Top 50 Biotech Startup Investors in Denmark (June 2026)
For AI agents: Short investor table (Markdown), Detailed investor list (Markdown)
| Investor | Relevant Deals | Geography | Stage | Focus | Round Size |
|---|---|---|---|---|---|
|
Novo Holdings
VC Fund
|
31 | United States, Denmark, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $9M–$130M |
|
BioInnovation Institute
VC Fund
|
19 | Denmark, Germany, Switzerland | Convertible Note, Pre-Seed, Debt Financing | Biotechnology, Medical, Health Care | $516k–$5.2M |
|
Vaekstfonden
VC Fund
|
16 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $440k–$4.6M |
|
Export and Investment Fund
VC Fund
|
15 | Denmark, United States, United Kingdom | Seed, Series A | Software, Biotechnology, Health Care | $390k–$84M |
|
Seed Capital
VC Fund
|
9 | Denmark, United States, United Kingdom | Seed, Series A | Software, Health Care, SaaS | $515k–$17M |
|
PSV
VC Fund
|
8 | Denmark, United States, United Kingdom | Seed, Pre-Seed | Software, Information Technology, SaaS | $88k–$4.7M |
|
Sunstone Life Science Ventures
VC Fund
|
6 | Denmark, Sweden, Switzerland | Series B, Series A | Biotechnology, Health Care, Medical | $5.5M–$52M |
|
Nordic Foodtech VC
VC Fund
|
6 | Finland, Denmark, Sweden | Seed, Series A, Pre-Seed | Biotechnology, Food and Beverage, Life Science | $549k–$18M |
|
Oskare Capital
VC Fund
|
6 | Italy, Denmark, United Kingdom | Seed, Series A, Pre-Seed | Health Care, Biotechnology, Medical | $1.2M–$5.9M |
|
Gilde Healthcare
VC Fund
|
6 | United States, The Netherlands, Germany | Series B, Series C, Series A | Biotechnology, Health Care, Medical | $8.8M–$120M |
|
RA Capital Management
VC Fund
|
5 | United States, United Kingdom, Canada | Series B, Series C, Post-IPO Equity | Biotechnology, Health Care, Therapeutics | $26M–$235M |
|
The Footprint Firm
VC Fund
|
4 | Denmark, Spain, Norway | Seed, Pre-Seed, Series A | Software, Renewable Energy, Energy Management | $730k–$18M |
|
ACME Capital
VC Fund
|
4 | United States, Denmark, Canada | Seed, Series A, Series B | Software, Health Care, Mobile | $1.6M–$70M |
|
PINC
VC Fund
|
4 | Sweden, Denmark, United Kingdom | Seed, Pre-Seed, Series A | Biotechnology, Agriculture, Food and Beverage | $549k–$7.4M |
|
West Hill Capital
VC Fund
|
4 | United Kingdom, Denmark, Germany | Series A, Seed | Software, Health Care, Financial Services | $1.8M–$15M |
|
DSM Venturing
VC Fund
|
4 | United States, Canada, Israel | Series A, Series B | Biotechnology, Health Care, Manufacturing | $3.5M–$32M |
|
Per Falholt
Angel
|
4 | Denmark | Pre-Seed, Series A, Seed | Biotechnology, Robotics, Biopharma | $5.9M–$20M |
|
HealthCap
VC Fund
|
4 | United States, Sweden, France | Series B, Series A | Biotechnology, Health Care, Medical | $5.7M–$88M |
|
VF Venture
VC Fund
|
4 | Denmark, United Kingdom, Iceland | Seed, Series A | Software, SaaS, Biotechnology | $1.2M–$22M |
|
Ysios Capital
VC Fund
|
4 | Spain, United States, Switzerland | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $2.2M–$135M |
|
HTGF (High-Tech Gruenderfonds)
VC Fund
|
3 | Germany, Switzerland, United States | Seed, Series A | Software, Biotechnology, Information Technology | $994k–$40M |
|
Atlantic
VC Fund
|
3 | Germany, Switzerland, United States | Seed, Series A, Pre-Seed | Software, Health Care, Financial Services | $850k–$32M |
|
Ugly Duckling Ventures
VC Fund
|
3 | Denmark, Sweden, Finland | Seed, Pre-Seed | Software, Information Technology, Artificial Intelligence | $876k–$5.5M |
|
Bioqube Ventures
VC Fund
|
3 | United States, France, Norway | Seed, Series A, Series B | Biotechnology, Therapeutics, Life Science | $4M–$108M |
|
Karolinska
VC Fund
|
3 | Sweden, Denmark, United States | Seed, Series A | Biotechnology, Health Care, Pharmaceutical | $1.3M–$73M |
|
Nicholas Francis
Angel
|
3 | Denmark, United States | Seed, Series A | SaaS, Robotics, Software | $854k–$7.1M |
|
Innovation Fund Denmark
VC Fund
|
3 | Denmark, United States | Grant, Pre-Seed, Seed | Software, Biotechnology, SaaS | $22k–$1.6M |
|
EIR Ventures
VC Fund
|
3 | Denmark, Sweden, United States | Series A, Seed | Biotechnology, Health Care, Therapeutics | $20M–$73M |
|
Unconventional Ventures
VC Fund
|
3 | Sweden, United Kingdom, Denmark | Seed, Pre-Seed, Series A | Health Care, Software, Wellness | $1M–$18M |
|
Sofinnova Partners
VC Fund
|
3 | France, United States, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Medical | $6M–$120M |
|
Thia Ventures
VC Fund
|
3 | United States, France, Denmark | Series A, Seed, Series B | Biotechnology, Health Care, Food and Beverage | $3.3M–$53M |
|
Blue Horizon Corporation
VC Fund
|
3 | United States, United Kingdom, Germany | Seed, Series A, Pre-Seed | Food and Beverage, Food Processing, Biotechnology | $450k–$28M |
|
NOON Ventures
VC Fund
|
3 | Denmark | Seed, Series A | Biotechnology, AgTech, Farming | |
|
Omega Funds
VC Fund
|
3 | United States, Switzerland, United Kingdom | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $14M–$208M |
|
Innovations Kapital
VC Fund
|
2 | Sweden, Denmark, United States | Series B, Series C | Biotechnology, Health Care, Software | $5.5M–$30M |
|
Steen Riisgaard
Angel
|
2 | Denmark | Pre-Seed | Life Science, Therapeutics, Biotechnology | |
|
SOSV
VC Fund
|
2 | United States, India, United Kingdom | Seed, Convertible Note, Pre-Seed | Biotechnology, Health Care, Software | |
|
Aescap Venture
VC Fund
|
2 | United Kingdom, Austria, Belgium | Series A, Series B | Biotechnology, Pharmaceutical, Chemical | |
|
Industrifonden
VC Fund
|
2 | Sweden, United States, Denmark | Series A, Seed | Software, Biotechnology, Information Technology | |
|
+ND Capital
VC Fund
|
2 | United States, Switzerland, Denmark | Series B, Series C, Series A | Biotechnology, Health Care, Medical | |
|
Northzone
VC Fund
|
2 | United States, Sweden, United Kingdom | Series A, Series B, Seed | Software, Information Technology, E-Commerce | |
|
Dawn Biopharma
VC Fund
|
2 | Denmark, France, Belgium | Seed, Series A, Series B | Biotechnology, Health Care, Therapeutics | |
|
Novo Ventures
VC Fund
|
2 | United States, United Kingdom, Switzerland | Series B, Series A, Series C | Biotechnology, Health Care, Medical | $8.5M–$143M |
|
Balderton Capital
VC Fund
|
2 | United Kingdom, United States, Germany | Series A, Series B, Series C | Software, FinTech, Financial Services | |
|
Newtree Impact
VC Fund
|
2 | Denmark | Seed | Biotechnology | |
|
Symrise
VC Fund
|
2 | United States, Sweden, Denmark | Series A, Seed | Biotechnology, Health Care, Pet | $4.2M–$7.4M |
|
FundersClub
VC Fund
|
2 | United States, Canada, India | Seed, Series A, Pre-Seed | Software, SaaS, Information Technology | $450k–$23M |
|
Megatrend Invest
VC Fund
|
2 | Denmark | Seed | Biotechnology, Manufacturing | $3.3M–$10M |
|
SR One
VC Fund
|
2 | United States, United Kingdom, Canada | Series A, Series B, Series C | Biotechnology, Health Care, Therapeutics | $3.7M–$150M |
|
Wellington Partners
VC Fund
|
2 | Germany, United States, United Kingdom | Series A, Series B | Health Care, Biotechnology, Medical | $3.1M–$55M |
| Access all 341 investors in Denmark Biotech startups. | |||||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Investor list
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: United States, Denmark, United Kingdom
Investor stats
- Total investments: 335
- Round size: Series A $9M–$120M; Series B $12M–$130M; Series C $30M–$118M
- Lead/follow: 40% lead, 60% follow
- Last fund: May invest from a new fund soon — raised $165M in 2018
Portfolio highlights
- AlloCure — AlloCure is a biotechnology company, develops cell therapies for the treatment of various kidney diseases, organ transplants, and multi-organ injuries. It offers biological therapeutics for acute kidney injuries. AlloCure is based in Burlington, Massachusetts. It has operations in Salt Lake City, Utah, and Hamburg, Germany.The company isdedicated to the development of off-the-shelf biological therapies to treat serious and debilitating diseases that afflict millions of people around the world. AlloCure's unique technology uses processed cells derived from human bone marrow to treat a wide variety of diseases. AlloCure was founded on the unique and proprietary technology developed by Dr. Christof Westenfelder and Dr. Axel Zander. Westenfelder and Zander are world-renowned scientists who have dedicated their careers to developing effective therapies for kidney disease. AlloCure has operations in Salt Lake City Utah and Hamburg Germany.
- PTC Therapeutics — Translating Science. Transforming Lives.
- Freeline — A leading biotechnology company focused on innovative liver directed gene therapies for bleeding disorders and other debilitating, chronic diseases
BioInnovation Institute is a biotechnology startup that offers entrepreneurs and researchers in life science. Early-stage life science start-ups are supported with up to 10 million DKK in funding, business acceleration, network, labs, and office space. It helps to early-stage start-ups within human health and planetary health. The startup'smission is to use its knowledge, network, funding, and infrastructure to incubate world-class life science and catalyze the commercialization of new solutions through start-ups.BioInnovation Institute was founded in 2018 and is based in Denmark.
Show more...Investment focus
- Industry: Biotechnology, Medical, Health Care
- Stage:Convertible Note, Pre-Seed, Debt Financing
- Geography: Denmark, Germany, Switzerland
Investor stats
- Total investments: 73
- Round size: Pre-Seed $516k–$5.2M; Debt Financing $549k–$1.4M; Convertible Note $549k–$1.5M
- Lead/follow: 90% lead, 10% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Loma Therapeutics — Loma Therapeutics is developing targeted immunotherapy for the effective and safe treatment of HPV infection, dysplasia, and cancer patients.
- metaLead Therapeutics — metaLead Therapeutics is to develop this peptide as a next-generation Pb poisoning treatment.
Vaekstfonden – The Danish Growth Fund – is the Danish state's investment fund. We strive to improve access to risk capital to enable Danish businesses to innovate, and to generate growth and new jobs. In close collaboration with banks and domestic and international private investors, we finance companies from all sectors nation-wide. We canaccompany you for the entire journey – from your company’s infancy through growth phases to expansion abroad and even to an initial public offering.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 196
- Round size: Seed $810k–$4.6M; Pre-Seed $440k–$1.2M
- Lead/follow: 28% lead, 72% follow
Portfolio highlights
- Captego — Unique, high-speed field data capture. Empower your inspectors & surveyors with our unique collection app. Benefit from high quality data to automate reports and data insights.
- LastSwab — LastSwab launched May 2019 through the crowdfunding platform Kickstarter. At $16 a swab, LastSwab is meant to last at least 1,000 uses and is the easy-to-clean, reusable alternative to the abundant waste caused by single-use swabs around the globe. The tip of the swab is made from medical silicone and nylon and comes in a biodegradable case made ofa corn-based material. LastSwab can be easily cleaned using soap and water and is also dishwasher safe. It comes in a standard swab for cleaning and a pointed swab for makeup application. Be the change and #SwabYourHabits.
- Donkey Republic — Donkey Republic is leading bike share service in Europe with footprint in more than 10 key cities in Europe. We operate our locations with partners, and use custom-branded bikes. Our software backbone is developed by us with unique features that ensure we respect public space with our hub-centric service model. At the same time, we maximizepredictability of bike availability and convenience. We pride ourselves in service innovation.
Denmark's Export and Investment Fund (EIFO) serves as a single point of contact for Danish firms seeking risk-tolerant government finance. We aspire to help successful enterprises that can expand the Danish economy and green the world on a daily basis, guided by professionalism and an international perspective.
Show more...Investment focus
- Industry: Software, Biotechnology, Health Care
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 119
- Round size: Seed $390k–$11M; Series A $4.7M–$84M
- Lead/follow: 36% lead, 64% follow
Portfolio highlights
- Woba — Woba is a SaaS aiming to support a stress-free work environment and minimise sick leave.
- Embankment — Dedicated to AIFs. Driven by technology, delivered by domain experts
- Landfolk — Landfolk is the new marketplace for the special holiday homes that are hidden around the country. We have hand-picked every single cottage, where there are proud and passionate hosts, who love their holiday homes, but also like to share it with others.
Seed Capital invests in Danish tech businesses with global ambitions. We are focused on "late seed"-stage companies, typically investing 1-3 MEUR in rounds of 1-6 MEUR. Proud backers of Trustpilot, Vivino, Lunar, Templafy, Dixa, Forecast, and many other great companies.
Show more...Investment focus
- Industry: Software, Health Care, SaaS
- Stage:Seed, Series A
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 186
- Round size: Seed $515k–$5M; Series A $3.5M–$17M
- Lead/follow: 27% lead, 73% follow
- Last fund: Likely still investing — raised $73M in 2021
Portfolio highlights
- Cardlay — Build your own white-label card and expense management solution with Cardlay. Our platform helps banks, fleets, and tech partners launch modern spend management solutions fast.
- Flatpay — Flatpay's fair, flat-rate pricing simplifies payments & cuts costs. Benefit from our comprehensive solution & superior customer service. Join us now!
- Odendo — On Odendo you can make a great deal on exciting products while supporting a good cause
PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV Hafnium, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment. Together, we can punch above our weight.
Show more...Investment focus
- Industry: Software, Information Technology, SaaS
- Stage:Seed, Pre-Seed
- Geography: Denmark, United States, United Kingdom
Investor stats
- Total investments: 138
- Round size: Seed $500k–$4.7M; Pre-Seed $88k–$2.5M
- Lead/follow: 35% lead, 65% follow
- Last fund: May invest from a new fund soon — raised $42M in 2020
Portfolio highlights
- Viio — Oveo creates cloud-based software that enables any company in any industry to easily discover, manage, optimise and secure all SaaS usage from one platform.We believe employees should be able to enjoy work, be agile, move fast and in turn become more innovative on behalf of the companies they work for. In a subscribed economy a “SaaS-Poweredworkplace” is the enabling foundation to make that vision come true and at Oveo we proud to contribute by making SaaS usage more transparent, manageable and secure. Theircloud-based software enable companies to easily push this transformation and as SaaS adoption continues to skyrocket we will be right here with you - building the platform to manage and optimize the lifecycle of your SaaS applications.
- Woba — Woba is a SaaS aiming to support a stress-free work environment and minimise sick leave.
- Legal Monster — Openli makes privacy transparent. Get control of your data processors and keep your DPAs up to date. Build trust and close deals faster all with Openli.
Sunstone Life Science Ventures is an independent European venture capital investment firm. We enable and empower life science therapeutics innovations.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: Denmark, Sweden, Switzerland
Investor stats
- Total investments: 56
- Round size: Series A $5.5M–$43M; Series B $9.6M–$52M
- Lead/follow: 14% lead, 86% follow
- Last fund: May invest from a new fund soon — raised $94M in 2019
Portfolio highlights
- Teitur Trophics — Teitur Trophics is a biotech company developing circular peptides for neurodegenerative diseases. The company was founded in 2020 and is headquartered in Aarhus, Denmark.
- Synendos Therapeutics — Synendos Therapeutics is a biopharmaceutical company that aims to develop breakthrough safe and effective therapies for unmet needs in neuropsychiatric disorders through modulation of a new drug target in the endocannabinoid system that enables restoration of natural functioning of the brain.
- TargED Biopharmaceuticals — TargED Biopharmaceuticals is a biotechnology company that develops first-in-class biological drugs to improve treatment of thrombosis.TargED stands for Targeted Enzyme Delivery. Their biological drugs are unique by using small antibodies (“VhH”) to deliver enzymes to sites of thrombosis, enabling ‘targeted’ thrombolysis.
We are investing in #FutureFood. Nordic FoodTech VC is the first fund in the Nordics investing explicitly in the future of food
Show more...Investment focus
- Industry: Biotechnology, Food and Beverage, Life Science
- Stage:Seed, Series A, Pre-Seed
- Geography: Finland, Denmark, Sweden
Investor stats
- Total investments: 28
- Round size: Seed $549k–$5.5M; Pre-Seed $1M–$1.9M; Series A $7.4M–$18M
- Lead/follow: 54% lead, 46% follow
- Last fund: Likely still investing — raised $49M in 2021
Portfolio highlights
- Enifer — Enifer Bio is an expert at squeezing every last drop of value from biorefining operations. The solution is built on decades of Finnish expertise to allow the production of valuable protein-rich feed from streams previously considered worthless. The company has developed a new, sustainable production process for high-quality fish feed raw material.The company's method enables the efficient production of a single cell protein from fish by-products as a raw material for fish feed. The protein can replace soy, which is commonly used in fish feed and whose cultivation poses ecological challenges, such as deforestation in South America.
- Hailia Oy — We mainstream seafood sidestreams with technology that upcycles them into tasty food products.
- NPHarvest — NPHarvest is a company with expertise in organic waste management, wastewater treatment, and nutrient recovery. NPHarvest is a research project aiming to enable efficient and profitable nitrogen recycling from waste flows to the fertilizer market, utilizing energy-efficient hydrophobic membrane stripping and ballasted sedimentation of phosphoruswith lime.
Oskare Capital is a venture capital firm.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Seed, Series A, Pre-Seed
- Geography: Italy, Denmark, United Kingdom
Investor stats
- Total investments: 8
- Round size: Seed $1.2M–$3.9M; Series A $4.8M–$5.9M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- Leva Clinic — Leva Clinic offers health care services for people with chronic pain. Their medical services include back pain, cancer pain, endometriosis, facial pain, fibromyalgia, joint pain, knee pain, multiple sclerosis, sciatica, and so on.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Herbolea Biotech — Unique bio-processing technologies NATURAL, SOLVENT-LESS Botanical extraction Learn more
Gilde Healthcare is a specialized European healthcare investor managing two business lines: a lower mid-market buy-out fund and a venture & growth capital fund. It has over €800 million ($900 million) under management and is actively looking to lead new investments in digital health, diagnostics, medical devices, therapeutics and healthcareservices. Gilde successfully builds healthcare businesses across Europe and US, investing up to €35 million in a single portfolio company.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, The Netherlands, Germany
Investor stats
- Total investments: 127
- Round size: Series A $8.8M–$65M; Series B $15M–$120M; Series C $21M–$75M
- Lead/follow: 38% lead, 62% follow
- Last fund: Likely still investing — raised $786M in 2023
Portfolio highlights
- Okami Medical — Okami Medical is a medical device company with a mission to address the evolving needs of patients and physicians through the development of innovative, versatile, and intuitive devices for the occlusion of peripheral vessels.
- ProVerum Medical — The ProVee stent from Proverum Medical uses 3-D geometry which mirrors and engages with the anatomy of the prostate. The system alleviates Lower Urinary Tract Symptoms (LUTS) by opening the prostatic urethra, applying radial force to the prostatic lobes.
- Endovascular Engineering — Endovascular Engineering is a preclinical stage company developing novel mechanical thrombectomy solutions to address peripheral indications.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!RA Capital Management is an investment advisor based in Boston specializing in the life-sciences and drug development sectors. The company's team has been investing since 2002 and is comprised of professionals with training in biology, chemistry, and medicine and also has industry and business development experience at the executive and boardlevels. The company invests in companies with promising technologies and products.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series B, Series C, Post-IPO Equity
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 448
- Round size: Series B $26M–$152M; Series C $40M–$200M; Post-IPO Equity $34M–$235M
- Lead/follow: 37% lead, 63% follow
- Last fund: Likely actively investing — fund raised in 2025
Portfolio highlights
- Curevo — focused on a new generation of adjuvanted subunit vaccines Learn More Our Focus We're dedicated to developing non-mRNA vaccines for unmet medical needs Curevo Vaccine is a clinical-stage biotech company dedicated to developing next-generation non-mRNA vaccines. We focus on one need at a time, allowing us to bring effective and better-tolerated vaccines to market quickly
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Terrestrial Bio — Vaxess engineers novel technologies that uniquely engage the human immune system, enabling improved efficacy and simplified access for vaccines and therapeutics.
The Footprint Firm is an advisory and investment company with a sole focus on sustainability.
Show more...Investment focus
- Industry: Software, Renewable Energy, Energy Management
- Stage:Seed, Pre-Seed, Series A
- Geography: Denmark, Spain, Norway
Investor stats
- Total investments: 23
- Round size: Seed $730k–$5.5M; Pre-Seed $775k–$4M; Series A $4.8M–$18M
- Lead/follow: 26% lead, 74% follow
Portfolio highlights
- FoodOp — Helping chefs cut food costs, reduce admin work, and drive sustainability. Menu planning, procurement, and reporting in one place.
- LastSwab — LastSwab launched May 2019 through the crowdfunding platform Kickstarter. At $16 a swab, LastSwab is meant to last at least 1,000 uses and is the easy-to-clean, reusable alternative to the abundant waste caused by single-use swabs around the globe. The tip of the swab is made from medical silicone and nylon and comes in a biodegradable case made ofa corn-based material. LastSwab can be easily cleaned using soap and water and is also dishwasher safe. It comes in a standard swab for cleaning and a pointed swab for makeup application. Be the change and #SwabYourHabits.
- Reel Energy — Reel empowers all companies to procure renewable electricity that makes a real difference for the climate.
ACME Capital is a venture capital and private equity firm that invests in breakthrough technologies that fuel platform shifts and disruptive business models that capitalize on new platforms. Its purpose is to support those founders who choose to take their capital. The firm was founded in 2018 and headquartered in San Francisco, California.
Show more...Investment focus
- Industry: Software, Health Care, Mobile
- Stage:Seed, Series A, Series B
- Geography: United States, Denmark, Canada
Investor stats
- Total investments: 171
- Round size: Seed $1.6M–$8.6M; Series A $4.4M–$30M; Series B $15M–$70M
- Lead/follow: 23% lead, 77% follow
- Last fund: Likely still investing — raised $300M in 2022
Portfolio highlights
- Cue — Cue helps users track their health at the molecular level, revealing the interplay of activity, food, and sleep. Consumers can track 5 key health and lifestyle indicators: inflammation, vitamin D, fertility, influenza, and testosterone in just minutes, at home. Cue sends the data via Bluetooth 4.0 to the user's smartphone, where the free Cueapp reveals the interplay of activity, food, and sleep shaping the user at a molecular level.
- NexGenT — Launch Your IT Career in Networking or Cyber Security Online With Our Military Grade Inspired Next Generation Training Programs. Go From Zero To Engineer within 6 months! Zero Up Front Tuition Options Available!
- BoomPop — Work culture resources, virtual event inspiration, team building ideas, and fresh perspectives on the future work, brought to you by the BoomPop team.
PINC was launched as Paulig Incubator in 2018 to help Paulig stay in the forefront of relevant innovations, as well as to contribute to a tastier, healthier and more sustainable planet. Today, our ambition is the same, but we have developed into a corporate venture arm. We aim for strategic, financial, and societal impact in our investments,fostering a sustainable food system for tomorrow. We are investing across the agrifood value chain in three primary impact themes: Improve planetary health and diet within the current food system: This includes innovations in agriculture and food security, such as advanced crop breeding or green fertilizers, innovative ingredients and next generation healthy foods, as well as solutions for tracking and improving climate and nature. Novel technologies to feed 10 BN people by 2050: Technologies needed to sustainably produce enough food for our growing population. This includes food production without land use change, such as precision fermentation and cell-culture. A circular system for food & materials: Regardless of whether we grow our food in soil or in bioreactors, the system needs to be circular. Some examples are upcycled ingredients, food from unused sources, new coating and packaging solutions, as well as technologies to prevent or make better use of side streams. We are looking for entrepreneurs in an attractive market space with an intrinsic drive to find a solution to the problem they are addressing, a clear and scalable plan for success, a reliable team and partners whom we can trust and work closely with.
Show more...Investment focus
- Industry: Biotechnology, Agriculture, Food and Beverage
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, Denmark, United Kingdom
Investor stats
- Total investments: 21
- Round size: Seed $823k–$7M; Pre-Seed $549k–$2.8M; Series A $4.1M–$7.4M
- Lead/follow: 24% lead, 76% follow
Portfolio highlights
- Scindo — Creating a novel biological process to turn low-value plastic landfill waste into high-value molecules.
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- BlueRedGold — Discover BlueRedGold - the home of exquisite Swedish Saffron, ethically grown and harvested with precision in Sweden. Experience the unparalleled quality of our saffron, perfect for culinary enthusiasts and chefs alike. Join us in embracing sustainable luxury.
West Hill Corporate Finance is a leading private equity venture capital firm providing EIS qualifying high-growth investments to private individuals.
Show more...Investment focus
- Industry: Software, Health Care, Financial Services
- Stage:Series A, Seed
- Geography: United Kingdom, Denmark, Germany
Investor stats
- Total investments: 58
- Round size: Seed $2.6M–$5.9M; Series A $1.8M–$15M
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Cercare Medical — Cercare Medical designs and develops a software tool for supporting acute stroke management, helping clinicians to evaluate the effect of a stroke. The software draws up the infarct-area within 30 seconds, locate perfusion area from images within 30 seconds and evaluate mismatch and generate a volume number of salvageable tissue. Cercare Medicalwas incorporated in 2013 under the name Combat Stroke and is based in Denmark.
- ATLANT 3D — Micro and nanodevices are built and tested within days instead of months or years.
- Formalize — A Whistleblower Software system made for accountants and lawyers that have clients, the whistleblower software system helps businesses implement a compliant solution that is both secure and transparent. their products are reporting links, case management, partner account they have designed a journey that makes feel safe about the process. AWS ishandling the physical security of the infrastructure, whistleblower software takes the shared responsibility of security between our cloud infrastructure and application seriously.
Innovators in nutrition, health, and beauty. Together, we bring progress to life by combining the essential, the desirable, and the sustainable.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Manufacturing
- Stage:Series A, Series B
- Geography: United States, Canada, Israel
Investor stats
- Total investments: 92
- Round size: Series A $3.5M–$32M; Series B $4.1M–$30M
- Lead/follow: 51% lead, 49% follow
- Last fund: May invest from a new fund soon — last raise in 2012
Portfolio highlights
- Vivici — Our mission is to meet the world's growing need for sustainable, nutritious and great tasting animal-free proteins.
- Verdezyne — Verdezyne was a privately-held company that employs its biological expertise and proprietary advanced computational algorithms to design and synthesize novel, high-diversity gene libraries for engineering proteins, metabolic pathways, and microorganisms. The company creates and harnesses this unique biological diversity to optimize commercialfermentation processes for the production of petrochemical replacements.
- NutriLeads — NutriLeads is an innovative startup that develops nutritional ingredients with demonstrated health effects. NutriLeads aims to catalyze nutritional health innovation in the food industry by partnering with relevant companies to identify promising lead ingredients, develop sustainable and commercially viable production processes, and initiatescientific & clinical programs to substantiate the health effects of these ingredients. Together we will bring the benefits of the proprietary ingredients to patients and consumers.
A passion and vision for chemistry and biotechnology led Per (born 1958) to Novo A/S, where he started his career as a research chemist. He subsequently held several managerial positions developing products for the detergent industry and rose to Director for Application Technology in the company’s new enzyme development division in 1995.Hemoved to Raleigh, N.C., to head the company’s U.S. application technology unit in 1997, returning to Denmark three years later as Corporate Vice President of the Enzyme Development and Application division. In April 2000, Per merged the Research and Development division into the newly formed Enzyme Business R&D.Per assumed his current position following Novozymes’ demerger from Novo Nordisk in 2000. As chief science officer, he has helped Novozymes develop a unique industrial biotechnology platform which delivers solutions to meet customer needs and support growth.Per holds a M.Sc. in Chemical Engineering from Technical University of Denmark (DTU). Committed to promoting education and research within the sciences, he was appointed Honorary Professor at DTU’s Institute for Systems Biology in 2010 and became Chairman of the Board in 2013. He is also Chairman of the Young Scientists association in Denmark.Per’s current external positions also include Chairman, DTU, board member of DHI Group, board member of ARTs Biologics A/S, and member of the Danish Council for Research Policy.
Show more...Investment focus
- Industry: Biotechnology, Robotics, Biopharma
- Stage:Pre-Seed, Series A, Seed
- Geography: Denmark
Investor stats
- Total investments: 5
- Round size: Series A $5.9M–$20M
- Lead/follow: 20% lead, 80% follow
Portfolio highlights
- Visibuilt — Visibuilt develops sustainable, bio-based asphalt binders made from mycelium. Replace fossil bitumen with visiBIT.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
HealthCap, a life science investor and company creator. Our motivation is to find innovative ideas and invest that could impact healthcare and society.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A
- Geography: United States, Sweden, France
Investor stats
- Total investments: 126
- Round size: Series A $5.7M–$55M; Series B $12M–$88M
- Lead/follow: 24% lead, 76% follow
- Last fund: May invest from a new fund soon — raised $209M in 2019
Portfolio highlights
- Positrigo — NeuroLF is an ultra-compact brain Positron Emission Tomography system. Our technology makes functional imaging accessible for people worldwide.
- Gesynta Pharma — Founded in 2017, Gesynta Pharma bases its R&D on research from the Karolinska Institutet. The most advanced drug candidate, GS-248, reduces inflammation and increases blood flow in the microvasculature, thereby having the potential to provide improved treatments for several serious diseases. In an ongoing clinical proof-of-concept study,GS-248 is being evaluated for its capacity to normalize vascular blood flow and reduce pain in patients with the autoimmune disease systemic sclerosis. Positive results from this study may lead to a rapid broadening of the development program towards additional indications, for example cardiovascular diseases and rheumatic diseases other than systemic sclerosis. Major shareholders include Industrifonden, Linc, Hadean Ventures, and a number of successful life science entrepreneurs. For more information, please visit www.gesynta.se
- Tribune Therapeutics — Tribune Therapeutics is a preclinical biopharmaceutical company building a promising pipeline of novel medicines to treat patients with a wide range of fibrotic diseases. It was founded in 2020 with funding from HealthCap and Novo Seeds.
Vaekstfonden makes equity investments in Danish companies with a track record as well as in young entrepreneurial, innovative enterprises with an ambition for global growth.
Show more...Investment focus
- Industry: Software, SaaS, Biotechnology
- Stage:Seed, Series A
- Geography: Denmark, United Kingdom, Iceland
Investor stats
- Total investments: 29
- Round size: Seed $1.2M–$9.1M; Series A $5.6M–$22M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Tame — ABOUT With Tame you can fully customise your virtual events, and make them fun, engaging & exciting to attend.- Apply your branding: Customise your virtual event completely - Personalised Welcome: Personal welcome message when attendees enter - Multiple stages: Broadcast content across multiple stages. - Live streaming: Stream live via anybroadcasting software - Pre-recorded videos: Broadcast pre-recorded videos as if it was live - Breakout sessions: Enable public or private breakout sessions. - Virtual Sponsor booths: Allow attendees to engage with sponsors live. - Customise Chat: Allow for 1:1 chat, group chat or session chat. - 1:1 Video Meetings: Empower social networking virtually.OUR COMPANY We are an experience-centric company, and we believe in the power of great experiences. Our international group of dreamers, creators and rule-breakers passionate about merging design and technology together, enables us to transform that into one truly amazing event platform.OUR PEOPLE The team behind Tame has an aggregated decades long experience of creating events and building products that solve real problems for real people. So, what got us here? Our ambition to change a broken event industry through innovation, customer obsession and a relentless focus on the great experience.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
- Performativ — Performativ develops modern solutions for the asset and wealth management industry. Our clients span from small investment advisors to enterprise banks.
Leading #lifesciences #venturecapital firm financing highly #innovative #biotechnology companies #worlwide.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: Spain, United States, Switzerland
Investor stats
- Total investments: 79
- Round size: Series A $2.2M–$63M; Series B $17M–$135M; Series C $27M–$80M
- Lead/follow: 30% lead, 70% follow
Portfolio highlights
- VarmX — VarmX is a pharmaceutical spin-off from the Leiden University Medical Center. The mission of VarmX is to develop and manufacture therapeutic proteins to instantaneously restore blood clotting in bleeding patients. The lead product in the pipeline of VarmX is PseudoXa. PseudoXa is a modified recombinant human coagulation factor X which is capable ofimmediately restoring blood clotting in the presence of direct factor Xa anticoagulants (DOACS) such as rivaroxaban, apixaban, and edoxaban.These factor Xa coagulants are taken by millions of patients world-wide for the prevention and treatment of thrombosis and stroke, but as a side effect severe bleeding often occurs. PseudoXa is capable of stopping and preventing such bleedings thus making the usage of DOACS much safer.
- Splice Bio — Splice Bio is a gene therapy company based on technology developed in the Muir Lab at Princeton University. The company is developing novel gene therapies based on its proprietary intein platform technology to treat patients that suffer from incurable genetic diseases. The company’s platform has the potential to address two existing limitations ofadeno-associated viruses (AAVs), both by increasing the size of the cargo gene that can be delivered and by expanding the range of tissues that can be targeted.
- Cytoki Pharma — Cytoki Pharma is a biotechnology company developing a portfolio of IL-22-based drugs as a new treatment paradigm for serious diseases involving epithelial injury.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!High-Tech Grunderfonds finances startups with growth potential. Its team of investment managers supports young companies with expertise, entrepreneurial spirit, and passion. The company focuses in the fields of digital tech, industrial tech, life sciences, chemistry, and related business areas. It also focuses on financial services in varioussectors.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Seed, Series A
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 557
- Round size: Seed $994k–$7.4M; Series A $3M–$40M
- Lead/follow: 34% lead, 66% follow
- Last fund: Likely still investing — raised $522M in 2022
Portfolio highlights
- QphoX — QphoX builds quantum modem device, connecting quantum computers across a quantum network.
- Zimory — Founded in 2007, Zimory provides carrier-grade cloud infrastructure management software that allows service providers, enterprises and cloud brokers to fully leverage the power and elasticity of cloud computing. Zimory’s intelligent Cloud Suite simplifies, automates and expedites the creation, launch and management of all types of cloudenvironments – whether public, private, virtual private or hybrid. Zimory software is also a key enabler of cloud marketplaces for enterprise services, applications and infrastructure. Headquartered in Berlin, Zimory has development centers in Erfurt, Germany and Minsk, Belarus, a subsidiary office in New York City and is expanding its expertise and presence globally.
- BlueID GmbH — Smart locks for professionals. BlueID delivers flexible, secure and convenient smart locks for all doors in and around your office.
Atlantic Labs supports and invests in mission-driven founders working on transformative technology ventures. <br><br>We partner with founders early, providing the capital, tools and network necessary to growing their companies and accompanying them on their entrepreneurial journey. We are currently active in areas including Digital Health, Future of Work, Machine Learning, Decentralized Networks, Mobility and Industrial Applications.
Show more...Investment focus
- Industry: Software, Health Care, Financial Services
- Stage:Seed, Series A, Pre-Seed
- Geography: Germany, Switzerland, United States
Investor stats
- Total investments: 199
- Round size: Seed $1.2M–$9.1M; Pre-Seed $850k–$3.8M; Series A $5.3M–$32M
- Lead/follow: 41% lead, 59% follow
- Last fund: Likely still investing — fund raised in 2022
Portfolio highlights
- Clue — Track your menstrual cycle with the Clue app, a women-led period and cycle tracker. Get science-based insights, predictions, and personalized tracking.
- bonify — Bonify, a Berlin based FinTech-Start-up, enables customers to benefit from their credit scoring and financial data. The company gives customers free and easy access to their credit score and let them upload additional relevant data. Then, it offers tools and personalized recommendations to help optimize the customer’s financial situation.Foundedin 2015 by key executives of McKinsey and Zalando, bonify has received significant funding from internationally leading VCs and successful entrepreneurs.
- tozero — Truly bringing lithium-ion battery waste tozero by recovering all critical matierlas, like lithium, nickel, cobalt, manganese, and graphite.
At Ugly Duckling Ventures, we make capital, know-how, and real-world application available to Nordic ventures at the seed & pre-seed stage. We are operational by nature and want to get in the grind as we excel at getting early-stage ventures ready for scale.
Show more...Investment focus
- Industry: Software, Information Technology, Artificial Intelligence
- Stage:Seed, Pre-Seed
- Geography: Denmark, Sweden, Finland
Investor stats
- Total investments: 18
- Round size: Seed $876k–$5.5M; Pre-Seed $917k–$1.7M
- Lead/follow: 67% lead, 33% follow
Portfolio highlights
- Eupry — Be in full control of your temperature compliance at all times. Collect temperature monitoring, mapping, and calibration in one GxP-compliant solution.
- Unioo — Unioo is a board portal that develops tools and software solutions to revolutionize and manage organizations and volunteer work.
- Kollektiv — Unleash your best self with tailored training plans, learning and support for running, swimming and cycling - from world-class-coaches and ex-athletes.
Bioqube Ventures is a specialist life sciences venture capital fund investing in European biotech companies developing innovative therapeutic assets and technologies. We put our venture creation experience at work to translate and de-risk scientific innovation, advancing our investment portfolio and maximising value for investors.Bioqube Venturesinvests through its independent fund “Bioqube Factory Fund I”: … an early stage venture capital fund – dedicated to advancing exciting science in vibrant European ecosystems to breakthrough therapies for patients.… a fit-for-purpose dual investment model – besides more classical investments in first investment rounds, we will have special attention for so called “Create” projects that require additional de-risking prior to creating new ventures. … a hands-on approach – the team is a mix of fund managers, sector experts and serial entrepreneurs that have a proven track record in successfully leading companies on their growth paths.Medtech, healthtech and diagnostics are not part of our current investment scope.
Show more...Investment focus
- Industry: Biotechnology, Therapeutics, Life Science
- Stage:Seed, Series A, Series B
- Geography: United States, France, Norway
Investor stats
- Total investments: 18
- Round size: Seed $5.7M–$21M; Series A $4M–$76M; Series B $23M–$108M
- Lead/follow: 33% lead, 67% follow
- Last fund: May invest from a new fund soon — last raise in 2020
Portfolio highlights
- Actithera — Actithera is a molecular radiotherapeutic company that develops radioligand therapies. It translates medicinal chemistry insights into new radioligand therapies (RLTs) and applies various molecular design strategies, including covalent targeting and an isotope-agnostic philosophy, to invent RLTs with significant differentiation and largertherapeutic windows.
- Commit Biologics — Add a description for facebook
- Primmune Therapeutics — Primmune Therapeutics is developing small molecule, orally-administered toll-like receptor 7 (TLR7) agonists to attack tumors and potentiate adaptive cancer immunotherapies, such as checkpoint inhibitors, to improve overall response rates and treatment durability.
Karolinska Development aims to create value for patients, researchers, investors and society by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatestreturn on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.Karolinska Development has developed a well-structured selection process to identify the most commercially attractive medical innovations screened by KIAB. Pharmaceutical development is a high-risk enterprise. In most cases, development projects fail because of side effects or insufficient efficacy. Successful selection of innovations is fundamental to Karolinska Development’s business model, which makes the inflow of new projects crucial. One key to success lies in selecting those innovations that can be developed from scientific findings to products and have significant commercial potential. To date, over 1,300 projects have been screened by KIAB.The portfolio companies are often founded together with the innovators and are initially operated as virtual companies with few or no employees. During the first six to twelve months, the companies normally have minimal fixed costs and technological development is outsourced.The innovator, who is often employed at an academic institution, normally participates as a board member and scientific advisor. The CEO of a portfolio company cooperates closely with a representative of Karolinska Development, who in most cases is also a board member of the company. The companies are capitalized to reach their next milestone, usually within a period of six to eighteen months. Development projects are continuously monitored, and those that do not meet their stipulated targets are discontinued. In the first three to four years, a portfolio company’s operating expenses are often limited to a few million Swedish kronor per year, which cover the cost of external studies and the salary of the staff. In subsequent years, Karolinska Development and other investors play an important role recruiting key expertise to the companiesKarolinska Development intends to realize value by exiting portfolio companies or through out-licensing of projects. Such transactions (especially out-licensing) are often structured as single upfront payments followed by payments based on predetermined milestones and royalties on sales. Although Karolinska Development has a flexible exit strategy, pharmaceutical products are, for two reasons, preferably exited at Phase II. First a successful Phase II study indicates that the pharmaceutical has an effect on patients, which is an important value-enhancing factor when negotiating out-licensing or sales. Secondly, finalizing product development and undertaking Phase III clinical trials frequently requires very large patient populations. In many cases this requires much greater resources than those available at Karolinska Development but these can be found in established pharmaceutical companies. Several licensing deals were closed in 2011 involving projects with a similar focus and development phase to Karolinska Development's projects.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pharmaceutical
- Stage:Seed, Series A
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 29
- Round size: Series A $1.3M–$73M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- BOOST Pharma — Boost Pharma: Developing a stem cell therapy for Osteogenesis Imperfecta.
- Modus Therapeutics — Modus Therapeutics is a Swedish drug development company developing sevuparin – a novel drug to treat people suffering from Sickle Cell Disease – a painful, inherited blood disorder affecting millions of people around the globe.
- Umecrine Cognition — Umecrine Cognition is a Swedish clinical-stage pharmaceutical company developing a novel class of drugs to treat neurological disorders of the brain.
Nicholas Francis is Co-founder at framebunker
Show more...Investment focus
- Industry: SaaS, Robotics, Software
- Stage:Seed, Series A
- Geography: Denmark, United States
Investor stats
- Total investments: 4
- Round size: Seed $854k–$7.1M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Waterplan — Waterplan is a SaaS platform for companies to manage water availability in their facilities.
- Reshape Biotech — Fully digital microbiology developed by Reshape Biotech
Innovation Fund Denmark invests in the development of new knowledge and technology creating growth and employment in Denmark. The Fund focuses on societal challenges, strengthens research, and increases innovation commitment within private companies.The Fund provides risk capital that enables cutting-edge initiatives to achieve resultssubstantially impacting the Danish society. Innovation Fund Denmark is also responsible for the future societal partnerships, where companies, universities, and public authorities will work together on challenges facing the society today.
Show more...Investment focus
- Industry: Software, Biotechnology, SaaS
- Stage:Grant, Pre-Seed, Seed
- Geography: Denmark, United States
Investor stats
- Total investments: 89
- Round size: Seed $66k–$1.3M; Grant $22k–$1.1M; Pre-Seed $64k–$1.6M
- Lead/follow: 31% lead, 69% follow
Portfolio highlights
- Prezio — Prezio is an electricity tariff data API for Europe. We aggregate, structure, and serve real-time and historical electricity pricing data - spot prices, retail tariffs, and grid fees - so energy applications don't have to build and maintain that data infrastructure themselves. Typical customers are developers and product teams building EVsmart charging, heat pump control, home batteries, and solar optimization tools - anything that needs to know what electricity actually costs, right now or over time, across European markets.
- SureShot — SureShot empowers you and your audience to become video co-creators. With our cutting-edge AI, capture, edit, and share electrifying videos that amplify the essence of every event.
- AlterEcho — AlterEcho is redefining aseptic manufacturing by decoupling human operators from cleanroom environments through First-Person View Remote Robotic Embodiment. Instead of direct intervention, operators control precision robotics remotely via first-person-view headsets and motion controllers, maintaining the dexterity and adaptability of humanoversight while eliminating contamination risks. This paradigm shift enables pharmaceutical manufacturers to enhance scalability, optimize facility layouts, and future-proof production against labor shortages and regulatory pressures. Unlike conventional automation, which struggles with edge cases and lengthy validation cycles, AlterEcho keeps human decision-making in the loop while generating the operational data and infrastructure that could enable more autonomous biomanufacturing in the future. A Techstars-backed venture, AlterEcho is not just iterating on aseptic workflows - it’s reengineering the fundamental relationship between humans and pharmaceutical production.
EIR Ventures is a new Life Science Venture Group in the Nordics.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Seed
- Geography: Denmark, Sweden, United States
Investor stats
- Total investments: 12
- Round size: Series A $20M–$73M
- Lead/follow: 58% lead, 42% follow
- Last fund: Likely still investing — raised $143M in 2021
Portfolio highlights
- Henlez — Henlez is a Danish startup company.
- Synklino — Synklino is a developer of a CMV-specific immunotoxin intended to eradicate the cytomegalovirus infection. The company's immunotoxin is highly effective, potent and fast-acting that kills lytic and latently infected cells, enabling patients to have long-term health benefits for transplantation.
- Galecto — Damora Therapeutics is working to fundamentally redefine care for people with blood disorders by bringing forward optimized therapies that dramatically improve patient outcomes.
Unconventional Ventures invests in startups in the pre-seed and seed stage led by diverse founders identifying as women, people of color, immigrants and/or LGBTQ+, building scalable impact tech companies in the Nordics and beyond.
Show more...Investment focus
- Industry: Health Care, Software, Wellness
- Stage:Seed, Pre-Seed, Series A
- Geography: Sweden, United Kingdom, Denmark
Investor stats
- Total investments: 17
- Round size: Seed $1M–$5.2M; Pre-Seed $1.5M–$2.8M; Series A $4.8M–$18M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- Flox Intelligence — Wildlife intelligence for critical infrastructure.
- AIRMO — Airmo is a space tech company that offers an independent data source that locates, quantifies, and tracks carbon dioxide and methane emissions through a small satellite constellation.
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series A, Series B, Series C
- Geography: France, United States, United Kingdom
Investor stats
- Total investments: 309
- Round size: Series A $6M–$67M; Series B $10M–$120M; Series C $12M–$100M
- Lead/follow: 45% lead, 55% follow
- Last fund: Likely still investing — raised $200M in 2023
Portfolio highlights
- Elicit Plant — We work with farmers around the world to meet the challenges of climate change and the impact of water scarcity on field crops.
- l'école — l'école AI is a computer vision-focused development platform. Its objective is to enable humans to use AI with purpose to change the future, beginning with a focus on speeding advances in life sciences using computer vision.
- EndoRon Medical — Endoron Medical develops an endovascular suture, like a device for the effective treatment of an abdominal aortic aneurysm.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!WE ARE AN EARLY-STAGE INVESTOR IN ONE OF THE MOST DYNAMIC AND ESSENTIAL FIELDS OF CURRENT HUMAN ENDEAVOR WE BRING ROBUST INVESTOR MUSCLE TO EARLY-STAGE VENTURES INVESTOR A specialized and focused investor Resources Powerful industry, substance and business resources Experience Wide networks and longstanding experience Team Yet, adaptability and speed of a lean, self-financed team
Show more...Investment focus
- Industry: Biotechnology, Health Care, Food and Beverage
- Stage:Series A, Seed, Series B
- Geography: United States, France, Denmark
Investor stats
- Total investments: 20
- Round size: Seed $3.3M–$20M; Series A $6.3M–$53M; Series B $24M–$50M
- Lead/follow: 10% lead, 90% follow
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- uFraction8 — Multi-award-winning, innovative, microfluidics-based filter systems to provide bio-manufacturers with energy-efficient & ultra-scalable bioprocessing systems.
- Clever Carnivore — Clever Carnivore is a cell-cultured meat startup that uses stem cell biology, recombinant protein, and bioengineering to create cost-effective lab grown meats. With the company's high-efficiency model, cruelty-free, environmentally friendly, and cost-competitive technology it aims to produce sausage, burgers, and chicken nuggets.
Blue Horizon is accelerating the transition to a sustainable food system that delivers outstanding returns for the planet and people.
Show more...Investment focus
- Industry: Food and Beverage, Food Processing, Biotechnology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, United Kingdom, Germany
Investor stats
- Total investments: 94
- Round size: Seed $2M–$12M; Pre-Seed $450k–$6.3M; Series A $2M–$28M
- Lead/follow: 32% lead, 68% follow
- Last fund: May invest from a new fund soon — raised $187M in 2021
Portfolio highlights
- WOW EARN — Discover WOW EARN, the all-in-one Web3 app with crypto mining, multi-chain wallet, staking NFTs, and marketplace dApps. Join the global Web3 community today.
- EV Biotech — We design and optimise your precision fermentation strains and processes, tailored to your success.
- foodforecast — AI supported solution to reduce food waste.
Noon Ventures is a Copenhagen-based, early-stage venture investor established in 2020. We invest in proven transformative technologies with the potential to impact environmental or climate challenges.
Show more...Investment focus
- Industry: Biotechnology, AgTech, Farming
- Stage:Seed, Series A
- Geography: Denmark
Investor stats
- Total investments: 6
- Lead/follow: 83% lead, 17% follow
Portfolio highlights
- Agrobiomics — Agrobiomics is a danish Agritech start-up, harnessing the power of soil bacteria and their metabolites as new biostimulants to help crops cope with abiotic stress such as drought.
- Enduro Genetics — Bioproduction can be difficult to scale to large cultivation volumes while keeping titers high. By applying game-changing synthetic biology technology, Enduro Genetics empowers our partner companies to maximize performance of all cells cultivated from their production strains.
- Lotus Microsystems — Lotus Microsystems offers miniaturized highly integrated point of load power converters. The devices are engineered for portable electronics manufacturers ready for usage whenever tiny power supply units are needed. Our devices offer up to 72% reduction in footprint compared to existing solutions with higher efficiency and reliability. Our plug andplay solutions enable our customers to innovate their electronics without worrying about power supply units.
We aim to invest in exceptional founders and entrepreneurs and impactful products and platforms across multiple therapeutic areas.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, Switzerland, United Kingdom
Investor stats
- Total investments: 149
- Round size: Series A $16M–$197M; Series B $35M–$162M; Series C $14M–$208M
- Lead/follow: 25% lead, 75% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Ousia Pharma — Ousia Pharma is paving the way for novel therapeutic strategies using peptide-drug-conjugates
- Andrew Alliance — OneLab is laboratory software to design and execute liquid handling protocols. Pipette+ for manual liquid handling pipetting and Andrew+ the pipetting robot
- NRG Therapeutics — energizing drug discovery in neurodegenerative diseases.
InnovationsKapital was founded in 1994 and is a leading independent venture capital firm for innovative growth companies in the Nordic region. The business, carried out from offices in and Stockholm, Gothenburg and New York, is focused on investments within ICT and Healthcare & Life Sciences, dynamic sectors that are rapidly expanding and whereNordic research plays an important role. The capital is provided by highly reputable Swedish and international institutional investors.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Series B, Series C
- Geography: Sweden, Denmark, United States
Investor stats
- Total investments: 19
- Round size: Series B $5.6M–$30M; Series C $5.5M–$15M
- Lead/follow: 11% lead, 89% follow
Portfolio highlights
- Silecs — PiBond manufactures materials used in electronic devices, including patterning materials for semiconductors and optical materials. We also develop complete solutions that allow our clients to focus on creating innovative products.
- SantoSolve — SantoSolve is developing topical analgesic products based on non-radioactive strontium as the active substance. The Development program was initiated based on experimental clinical use of strontium-based products showing evidence of strong local analgesic effects on several localized pain conditions of both nociceptive and neuropatic origin. Nosignificant adverse effects associated with the treatment was reported.The company’s lead product, 2PX, is topically administered, utilizing dermal penetration enhancers for delivery of the active agent to its subdermal site of action. Phase I safety and pharmacology studies showed the active agent to have low systemic bioavailability, and only few and minor adverse effects were observed at the site of administration. In open label Phase II clinical trials, the product has shown strong analgesic effect in both nociceptive and neuropatic pain conditions. In follow up, placebo controlled trials, the analgesic effect of the product has been further documented. In the company’s most advanced pain indication under study, osteoarthritis, the company has recently completed the Phase II program.These trials supports the open label results and document statistically that the analgesic effect in patients treated with 2PX is superior to that observed with placebo treatment.
- Action Pharma — Providing a surprisingly human shopping experience. Trusted and secure. Millions of domains to choose from.
Steen Riisgaard
Show more...Investment focus
- Industry: Life Science, Therapeutics, Biotechnology
- Stage:Pre-Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Lead/follow: no public data
Portfolio highlights
- Octarine Bio — Octarine Bio is a world leading synthetic biology platform with a core mission to drive bio-based, sustainable solutions to address the most pressing planetary issues through innovation & exploration. Inspired by nature, to protect nature.
- Synamics Therapeutics — Synamics Therapeutics uses AI and predictive modeling for precision oncology and improved drug discovery. Our adaptive medicine approach helps prolong drug effectiveness and improves outcomes for patients with intractable cancers. Learn more about Synamics Therapeutics and how we leverage AI for personalized, adaptive cancer therapies.
SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Software
- Stage:Seed, Convertible Note, Pre-Seed
- Geography: United States, India, United Kingdom
Investor stats
- Total investments: 1475
- Lead/follow: no public data
Portfolio highlights
- unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
- NovoNutrients — NovoNutrients is working to turn waste CO2 into high-value, low-cost proteins and additives for food and feed by developing proprietary microbes and advanced gas fermentation systems.
- Sodex Innovations — Sodex Innovations is a company which is specialized in developing assistance-systems and automating-kits for excavators
The Aescap funds invest in highly innovative publicly traded biotech/life sciences companies. We're able to select the promising companies
Show more...Investment focus
- Industry: Biotechnology, Pharmaceutical, Chemical
- Stage:Series A, Series B
- Geography: United Kingdom, Austria, Belgium
Investor stats
- Total investments: 18
- Lead/follow: no public data
Portfolio highlights
- Orphazyme — Orphazyme develops innovative new therapies for the treatment of a family of serious genetic disordes called lysosomal storage diseases, and is based on discoveries emerging from the academic laboratory of its scientific founders: Professor Marja Jäättela and Thomas Kirkegaard Jensen from the Danish Cancer Society (Kræftens Bekæmpelse).Orphazyme is based in Copenhagen and has established collaborations with top-tier academic institutions in Europe and USA.
- Avantium — Build a sustainable future with Avantium. Leading the change in green chemistry and innovative solutions.
- F-Star Therapeutics — F-star is a clinical stage biotech developing next generation immunotherapies to transform the lives of patients with cancer. We are developing transformational cancer immunotherapies for patients who have few remaining options.
Industrifonden is a Nordic evergreen venture capital firm with a fund size of $600m, that focuses on early-stage technology and life science companies with international potential. The company works long term with the entrepreneurs we invest in, and have a strong track record of building game changing companies. Industrifonden-backed companiesinclude tech companies Qlik, Arcam, Soundtrack Your Brand, Fishbrain, and life science companies CellaVision, Oncopeptides and AMRA.
Show more...Investment focus
- Industry: Software, Biotechnology, Information Technology
- Stage:Series A, Seed
- Geography: Sweden, United States, Denmark
Investor stats
- Total investments: 161
- Lead/follow: no public data
Portfolio highlights
- Fibbl — Fibbl is the world's first cost-effective end-to-end solution for 3D and AR focused visual marketing. Integrate 3D & AR into e-commerce and marketing in minutes.Fibbl have industrialized the process of producing photorealistic 3D models for consumer products from global brands. Fibbl has the world's largest 3D model database forconsumer products.Learn more - https://www.fibbl.com/
- Agteria Biotech — Agteria Biotech is an innovative biotech startup dedicated to mitigating methane emissions in cattle through our groundbreaking compound. By promoting sustainable practices in livestock farming, we aim to engage investors and dairy companies interested in eco-friendly solutions. Partner with us to t
- Senseworks — Senseworks is an insight platform that enables colleagues to collaborate effectively with customers by providing a single source of truth for accounting data.
+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series C, Series A
- Geography: United States, Switzerland, Denmark
Investor stats
- Total investments: 58
- Lead/follow: no public data
Portfolio highlights
- Vandria — At the vanguard of Mitochondrial research
- Constructive Bio — Constructive is a ground-breaking method for creating wholly artificial genomes and rewriting the genetic code of living things.
- PulseSight Therapeutics — PulseSight is an ophthalmology drug development company creating novel, non-viral gene therapies with minimally invasive delivery technology to address the unmet need for treatments against severe retinal diseases leading to blindness.
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!Northzone is a multi-stage venture capital fund that seeks to invest in the healthcare, semiconductors, software, hardware, artificial intelligence, blockchain, and gaming industries.
Show more...Investment focus
- Industry: Software, Information Technology, E-Commerce
- Stage:Series A, Series B, Seed
- Geography: United States, Sweden, United Kingdom
Investor stats
- Total investments: 278
- Lead/follow: no public data
Portfolio highlights
- Nivoda — Nivoda provides jewellery businesses with a simple solution to strengthen profits, increase efficiency and accelerate growth with its B2B diamond marketplace. Designed to save you time and money whilst giving you access to the world’s diamond supply at the best prices with zero inventory risk, Nivoda is trusted by thousands of retailers all overthe globe.
- Tana — Tana is a software development company that reinvents how humans, teams, and computers work together. Tana was founded in 2020 and was headquartered in Oslo, Norway.
- Berry Street — Nutrition therapy by registered dietitians covered by insurance.
Dawn Biopharma is a global investment firm of KKR.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Seed, Series A, Series B
- Geography: Denmark, France, Belgium
Investor stats
- Total investments: 7
- Lead/follow: no public data
Portfolio highlights
- ADCendo — ADCendo ApS is a biotech company dedicated to developing new types of anti-cancer drugs. We focus on antibody-drug conjugates (ADCs) directed at novel targets, that have been found to be overexpressed by several cancer forms, that are all characterized by a significant unmet need for novel treatment.
- Antag Therapeutics — Antag Therapeutics operator of a biotechnology company intended to develop metabolic and anti-obesity therapeutic drugs.The company specializes in the development of peptide-based GIP receptor antagonist in order to monitor dietary-related metabolic diseases through the infusion, enabling the healthcare industry to decrease blood flow and lipiduptake in adipose tissue in an efficient manner.
- Bambusa Therapeutics — Bambusa Therapeutics operates as biotechnology company, that focuses on developing bispecific antibodies.
Novo Holdings is a world-leading life science investor with a focus on creating long-term value.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Medical
- Stage:Series B, Series A, Series C
- Geography: United States, United Kingdom, Switzerland
Investor stats
- Total investments: 79
- Round size: Series A $8.5M–$74M; Series B $14M–$75M; Series C $13M–$143M
- Lead/follow: 35% lead, 65% follow
Portfolio highlights
- PanOptica — PanOptica is a biopharmaceutical company developing a topical eye drop for the treatment of eye diseases caused by abnormal or leaky blood vessels.
- Galera Therapeutics — Developing novel therapies that have the potential to reduce radiotherapy-induced toxicities and improve the anti-cancer efficacy of radiation therapy
- Reneo Pharmaceuticals — OnKure Therapeutics - Writing the Next Chapter in Precision Medicines for Patients With Cancer
In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn.
Show more...Investment focus
- Industry: Software, FinTech, Financial Services
- Stage:Series A, Series B, Series C
- Geography: United Kingdom, United States, Germany
Investor stats
- Total investments: 340
- Lead/follow: no public data
Portfolio highlights
- Agave Games — Agave Games is a mobile games publishing company and provides unique experiences
- Grand Games — Grand Games is shaping the future of gaming by creating genre-defining games played by millions worldwide.
- Lindus Health — Lindus Health. From recruitment to delivery, we accelerate clinical trials. Our mission is to make health research accessible for everyone, everywhere.
We invest in disruptive and encouraging Agri-Food tech and Food Loss companies, reshaping our food systems in order to solve the current & future problems of production.
Show more...Investment focus
- Industry: Biotechnology
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 4
- Lead/follow: no public data
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Yeastup — Yeastup transforms brewer's yeast into proteins & fibers for food & supplements. Contact us for sustainable ingredient solutions.
- New School Foods — Salmon, made from plants. Clean label with ALL the Omega-3s, NONE of the mercury. Made in Canada.
About 30,000 products - 6,000 customers in roughly 160 countries. First synthesis of vanillin in 1874.
Show more...Investment focus
- Industry: Biotechnology, Health Care, Pet
- Stage:Series A, Seed
- Geography: United States, Sweden, Denmark
Investor stats
- Total investments: 6
- Round size: Series A $4.2M–$7.4M
- Lead/follow: 50% lead, 50% follow
Portfolio highlights
- EvodiaBio — Mirroring nature with pioneering bioscience for natural flavors
- Indevex AB — Indevex is a science-based and privately owned biotech company from Sweden. A natural and reliable partner, providing evidence based natural nutrition concepts based on the patented NGC™ Formula.
- Bond Pet Foods — We make vegan and protein-rich pet food and treats formulated by board-certified veterinary nutritionists.
FundersClub focuses on Seed and early stage investments. Investments include Coinbase, Instacart, Flexport, Le Tote, Teespring, Memebox, GitLab.FundersClub is the world's first online venture capital platform. Backed by Y Combinator, First Round Capital, Spark Capital, Intel Capital, Draper, Andreessen Horowitz, Felicis Ventures, and more;FundersClub Inc. was founded in 2012 and is based in the United States.
Show more...Investment focus
- Industry: Software, SaaS, Information Technology
- Stage:Seed, Series A, Pre-Seed
- Geography: United States, Canada, India
Investor stats
- Total investments: 304
- Round size: Seed $800k–$5.3M; Pre-Seed $450k–$1.7M; Series A $5.1M–$23M
- Lead/follow: 5% lead, 95% follow
- Last fund: May invest from a new fund soon — raised $448k in 2019
Portfolio highlights
- Zingbus — zingbus.com - India's Largest Online Ac Bus Booking Platform Offers Ac Bus Travels, Book AC Volvo Bus Tickets at Best Rates. Easy Cancellation & Instant Refund.
- Embrace — Stay informed with Embrace's mobile monitoring solutions. Optimize app performance & user experience with our comprehensive platform. Learn more now.
- Gecko Robotics — To collect and make useful physical data in order to protect civilization's most critical infrastructure
Megatrend Invest is an investment Firm.
Show more...Investment focus
- Industry: Biotechnology, Manufacturing
- Stage:Seed
- Geography: Denmark
Investor stats
- Total investments: 2
- Round size: Seed $3.3M–$10M
- Lead/follow: 0% lead, 100% follow
Portfolio highlights
- Biograil — Biograil, founded in 2019 and led by CEO Karsten Lindhardt, is using injection molding to manufacture a device contained in a standard size capsule able to deliver active substances into the gastrointestinal wall. The Biograil device avoids mechanical moving components and makes use of the body’s own peristaltic forces to facilitate the delivery ofthe biologic efficiently into the gastrointestinal wall.
SR One Capital Management is a leading trans-Atlantic biotech venture capital firm that partners with top entrepreneurs, scientists and investment partners to seek to build elite biotechnology companies. Our mission is to translate ground-breaking technologies into next generation medicines to benef
Show more...Investment focus
- Industry: Biotechnology, Health Care, Therapeutics
- Stage:Series A, Series B, Series C
- Geography: United States, United Kingdom, Canada
Investor stats
- Total investments: 189
- Round size: Series A $3.7M–$140M; Series B $15M–$114M; Series C $22M–$150M
- Lead/follow: 32% lead, 68% follow
- Last fund: Likely still investing — fund raised in 2023
Portfolio highlights
- Turning Point Therapeutics — The Investor Relations website contains information about Turning Point Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts.
- Nkarta Therapeutics — Nkarta seeks to improve upon the efficacy of cell therapy, making it more potent, better tolerated and more rapidly available to a broad population of patients with a variety of hematologic and solid tumor malignancies.While T-cell therapy, often known as CAR-T, has proven successful in certain cancer indications, its promise has been limited toa few hematologic malignancies and the side effects can be severe. Natural Killer cells are the immune system’s first responders against diseases and pathogens. Unlike T cells, they have an inherent ability to target tumor cells without genetic alteration, and therefore hold significant promise in the development of potent therapies that can be used more readily for diverse tumor types. Nkarta’s differentiated cell therapy approach is designed to boost and enhance the inherent power of Natural Killer cells to target and destroy tumor cells, while also offering a better tolerated safety profile.
- River Vision Development — River Vision Development develops RV001, a protein therapy for the treatment of Graves’ Orbitopathy (GO). River Vision Development was founded in 2011 and is based in New York, New York.
Wellington Partners is a venture capital firm that invests in technology and life sciences companies, focusing on Digital Media, Software, Electronics & Photonics, Resource Efficiency, and Biotech/Life Sciences. It is committed to providing outstanding entrepreneurs with the necessary resources to fund their strategies. We typically leadfinancing rounds ranging from € 0.5 million to € 20 million. Depending on the maturity of the company, its own commitment can go as high as € 15 million.Wellington was established in 1998 and has offices in Munich, London, and Zurich.
Show more...Investment focus
- Industry: Health Care, Biotechnology, Medical
- Stage:Series A, Series B
- Geography: Germany, United States, United Kingdom
Investor stats
- Total investments: 194
- Round size: Series A $3.1M–$33M; Series B $7.7M–$55M
- Lead/follow: 30% lead, 70% follow
- Last fund: May invest from a new fund soon — raised $222M in 2019
Portfolio highlights
- nyra health — myReha is an artificial intelligence and evidence-based neurological research tablet app that offers a revolutionary form of therapy. myReha was founded in 2020 and was headquartered in Vienna, Austria.
- UiPath — Reinvent your workplace with the leading robotic process automation platform and learn how UiPath can help your company become a fully automated enterprise.
- UroMems — The device is developing an active implantable medical device based on the cutting edge technologyl in the field of embedded systems and micro-technologies for the development of its products.
Biotech Investor funding in Denmark at a glance
Stats across 338 deals from 341 investors.
Access all 341 investors in Denmark Biotech startups.
Open ListFAQ
Is Shizune data fresh/accurate?
Shizune has monitored hundreds of funding sources since 2020.
Our investor database is updated every day, so investor data is always fresh.
All metrics are calculated from confirmed public rounds, so the data is accurate.
Can I download investor list?
To download the Biotech Investors in Denmark investor list, create a Shizune account. This investor list will be added to your saved investors and available for download in the export section.
You can also enrich the investor list with investor emails, phones, LinkedIns, and other contact data.
Can I access investor database?
To access all 341 investors investing in Denmark Biotech startups and 48,091+ more investors, create a Shizune account.
Shizune has a database of 48,091 investors. Our investor database is fresh and updated daily.
The Shizune investor database has information on investor investment focus, investor contact data, and full investor portfolio since 2020.
You can enrich with email and download the data.
Does Shizune have investor emails and contacts?
Shizune enriches investors with contact data that includes: email, phones, LinkedIn, socials, website, and others.
To guarantee the highest discovery rate, we search across 20+ contact search tools.
To maximize delivery rate and reduce bounce rate, we validate emails.
You can enrich your investor list with Shizune. Download it too.
What is Shizune?
Shizune is a 48,091 investor database updated daily.
With Shizune you can:
- browse the database
- use smart matching
- enrich with emails
- download
All you need to find investors for your startup.
Who is Shizune for?
Shizune is built for startup founders by startup founders.
If you are looking for funding for your startup, try the Shizune database — we have investors for every stage, industry, and country.
Is Shizune free?
Shizune is free forever. You can search and browse investors for free.
Email search and export are paid features.
For full info, visit our pricing.
Who built Shizune?
Shizune is built by founders with the goal of helping all founders raise funding no matter where they are.
Contact 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!